Ordering
Available Variants5 mg
CHA.21047-5mg
Price
€65.21
Available – Dispatch in 14 days
25 mg
CHA.21047-25mg
Price
€343.40
Available – Dispatch in 14 days
25 g
CHA.21047-25g
Price
€55.76
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.21047-5mg | €65.21 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.21047-25mg | €343.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 g | CHA.21047-25g | €55.76 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H25NO3 · CH4O3S |
|---|---|
| CAS Number | 188591-67-5 |
| Molecular Weight | 423.52 |
| NACRES | NA.77 |
| PubChem Substance ID | 329823794 |
| UNSPSC Code | 51111800 |
| MDL number | MFCD12546332 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS06
GHS09
  GHS06,GHS09
|
|---|---|
| signalword | Danger |
| hcodes | H301,H319,H400 |
| pcodes | P273 - P301 + P310 + P330 - P305 + P351 + P338 |
| Hazard Classifications | Acute Tox. 3 Oral - Aquatic Acute 1 - Eye Irrit. 2 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
CP-101606 mesylate, also known by its CAS number 760-78-1, is a potent and selective inhibitor of the enzyme acetylcholinesterase. This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of neurological disorders such as Alzheimers disease. The mesylate salt form of CP-101606 exhibits improved solubility and stability, making it a more viable candidate for pharmaceutical development. Research has demonstrated that CP-101606 mesylate can effectively cross the blood-brain barrier, allowing it to reach therapeutic concentrations in the central nervous system. As a result, this compound has shown promise in preclinical trials, with potential benefits including improved cognitive function and neuroprotection. Further investigation is necessary to fully elucidate the therapeutic potential of CP-101606 mesylate and its potential role in the treatment of neurodegenerative diseases.
